Evidence map›Paper›PMID 28009883›Full record

ReviewLab on a chip2017

Thermoplastic nanofluidic devices for biomedical applications.

Kumuditha M Weerakoon-Ratnayake, Colleen E O'Neil, Franklin I Uba, Steven A Soper

Abstract readReview
In one paragraph

Review in Lab on a chip, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Fully 3D printed fluidic devices with integrated valves and pumps for flow injection analysis.Analytical methods : advancing methods and applications · 2021
    Article
  12. Article
  13. Glioma-on-a-Chip Models.Micromachines · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kumuditha M Weerakoon-RatnayakeDepartment of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, USA and NIH Biotechnology Resource Center of Biomodular Multiscale Systems for Precision Medicine, USA.ORCID 0000-0002-6839-4515
Colleen E O'NeilDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA and NIH Biotechnology Resource Center of Biomodular Multiscale Systems for Precision Medicine, USA.
Franklin I UbaDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Steven A SoperDepartment of Chemistry and Department of Mechanical Engineering, University of Kansas, Lawrence, KS 66047, USA. ssoper@ku.edu and Kansas University Medical Center NIH Cancer Center, Kansas City, KS 66106, USA and NIH Biotechnology Resource Center of Biomodular Multiscale Systems for Precision Medicine, USA and Ulsan National Institute of Science and Technology, Ulsan, South Korea.

Funding

Single-Molecule Processing: Detection and Identification of Single DNAs, RNAs, and Proteins using Immobilized Nanoscale Enzymatic Reactors (INERs) and Nanoscale ElectrophoresisP41EB020594 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sunggook Park · 2015 to 2026
$15.2M
Polymer-Based Modular Systems with Nanosensors for DNA/RNA SequencingR21HG006278 · NHGRI · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI SOPER, STEVEN ALLAN · 2011 to 2012
$616k
NHGRI NIH HHS R21 HG006278NIBIB NIH HHS P41 EB020594
6 · The paper itself

Abstract

Microfluidics is now moving into a developmental stage where basic discoveries are being transitioned into the commercial sector so that these discoveries can affect, for example, healthcare. Thus, high production rate microfabrication technologies, such as thermal embossing and/or injection molding, are being used to produce low-cost consumables appropriate for commercial applications. Based on recent reports, it is clear that nanofluidics offers some attractive process capabilities that may provide unique venues for biomolecular analyses that cannot be realized at the microscale. Thus, it would be attractive to consider early in the developmental cycle of nanofluidics production pipelines that can generate devices possessing sub-150 nm dimensions in a high production mode and at low-cost to accommodate the commercialization of this exciting technology. Recently, functional sub-150 nm thermoplastic nanofluidic devices have been reported that can provide high process yield rates, which can enable commercial translation of nanofluidics. This review presents an overview of recent advancements in the fabrication, assembly, surface modification and the characterization of thermoplastic nanofluidic devices. Also, several examples in which nanoscale phenomena have been exploited for the analysis of biomolecules are highlighted. Lastly, some general conclusions and future outlooks are presented.

Indexed as

BiotechnologyHot TemperatureMicrofluidic Analytical TechniquesNanostructuresPlasticsPlastics

Identifiers

PMID28009883
PMCPMC5285477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.